Patient portal

Bautista group

Early clinical trials in pediatric hemato-oncology

Our early clinical trials group bridge the gap between laboratory discovery and clinical application. Our focus is on the design and implementation of innovative Phase I and II trials to provide children with refractory or relapsed hematological malignancies access to the latest therapeutic breakthroughs. By integrating deep clinical expertise with regulatory science and biological insights, we aim to transform the landscape of pediatric drug development. We do this work collaboratively with academic groups in Europe and overseas (e.g. IBFM, ITCC, PEDAL) and investigators from around the world, and in close contact with pharmaceutical industry, and, very importantly, with patient’s advocates.

Contact

Paco Bautista

Paco Bautista

Pediatric oncologist

Precision medicine and myeloid & lymphoid malignancies  

We focus on identifying and validating novel therapeutic targets in pediatric acute lymphoblastic leukemia (ALL), malignant lymphoma (ML), pediatric acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and Langerhans cell histiocytosis (LCH). By utilizing a "bench-to-bedside" approach, we translate biological findings into targeted clinical trial arms, ensuring that each child receives the most promising therapy based on their unique molecular profile. Furthermore, we integrate monitoring and treatment adaptation strategies to optimize therapeutic efficacy and safety throughout the treatment course. Key initiatives from the members of our group include:

  • HEM-iSMART (International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children), precision medicine platform for patients with relapsed/refractory ALL

  •  MYELOPED trial, to evaluate multiple novel agents simultaneously for patients with myeloid malignancies.

  • GLO-BNHL, a global study of novel agents in pediatric and adolescent relapsed and refractory B-Cell non-Hodgking lymphoma

“Bringing tomorrow’s medicines to the children who need them today through innovative clinical research”

Paco Bautista

Research group leader and pediatric oncologist

Collaborative research ecosystem

Our group operates at the heart of the Máxima research community. We work in close synergy among the three Group Leaders in New Drug Development in the different domains, covered by Dr van der Lugt in brain tumors and Dr Schoot in solid tumors. Recognizing that progress is measured beyond initial response, we collaborate with other groups to integrate Quality of Life (QoL) assessments considerations into our trial designs.

Regulatory science and trial innovation

In collaboration with the ITCC (Innovative Therapies for Children with Cancer) consortium and the ACCELERATE platform, our group leads the modernization of clinical trial operations. We focus on developing adaptive master protocols and streamlining regulatory pathways. Our goal is to reduce the time from drug discovery to trial activation, ensuring efficient, safe, and high-quality drug evaluation processes across Europe.

Academic-led advanced therapeutics

A core priority is the support for development and implementation of academic-initiated trials, particularly in the field of cellular immunotherapy. In close collaboration with the Princess Máxima Cell  and Gene Therapy Unit, we drive the clinical translation of next-generation treatments, such as CAR-T cell therapies, from early development through to complex clinical implementation. Key initiatives from the members of our group include:

  • INFLUENCE trial, a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia to evaluate the impact on event free survival by optimizing fludarabine exposure during lymphodepletion for CART cell therapy.

  • ARI0001 trial, a Phase 2 clinical trial to evaluate the efficacy and safety of varnimcabtagene autoleucel (ARI-0001) for first relapsed/refractory paediatric B-cell acute lymphoblastic leukaemia. This trial is leaded by our colleagues in Hospital Sant Joan de Deu in Barcelona (Dr Rives), and our institution forms part of the academic consortia to run this study at an international level, which was awarded by the prestigious ATTRACT grant.

Institutional capacity & sustainability

We are committed to building a robust infrastructure for pediatric clinical trials at the Princess Máxima Center. This involves the professionalization of trial management, data integrity, and fostering long-term partnerships with academic and, independently, with industrial stakeholders to ensure the financial and operational sustainability of our research initiatives.

Grants and publications

Our research group

Join us

To cure every child with cancer, we are looking for the best scientists! Working in a top organization demands highly qualified employees who perform to their utmost in a work environment with continuous motivation for improvement. Do you recognize yourself in our core values as groundbreaking and passionate? Explore the job opportunities in our research department.

Explore job opportunities